Myo-Inositol Reduces β-Catenin Activation in Colitis

Authors

Emily M. Bradford, University of KentuckyFollow
Corey A. Thompson, University of KentuckyFollow
Tatiana Goretsky, University of KentuckyFollow
Guang-Yu Yang, Northwestern University
Luz M. Rodriguez, National Cancer Institute
Linheng Li, University of Kansas
Terrence A. Barrett, University of KentuckyFollow

Abstract

AIM

To assess dietary myo-inositol in reducing stem cell activation in colitis, and validate pβ-catenin^S552 as a biomarker of recurrent dysplasia.

METHODS

We examined the effects of dietary myo-inositol treatment on inflammation, pβ-catenin^S552 and pAkt levels by histology and western blot in IL-10^-/- and dextran sodium sulfate-treated colitic mice. Additionally, we assessed nuclear pβ-catenin^S552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia.

RESULTS

In mice, pβ-catenin^S552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, pβ-catenin^S552 staining discriminated ulcerative colitis patients with a history of LGD from those with benign disease.

CONCLUSION

Enumerating crypts with increased numbers of pβ-catenin^S552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.

Document Type

Article

Publication Date

7-28-2017

Notes/Citation Information

Published in World Journal of Gastroenterology, v. 23, issue 28, p. 5115-5126.

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Digital Object Identifier (DOI)

https://doi.org/10.3748/wjg.v23.i28.5115

Funding Information

Supported by Veterans Affairs Merit Award, No. IO1CX001353 (to Barrett TA); National Institutes of Health, No. 2R01DK095662-06A1 (to Barrett TA); the National Cancer Institute at the National Institutes of Health, No. N01-CN-35157 (to Bergan R); the Training Program in Oncogenesis and Developmental Biology through the National Cancer Institute, No. NCI T32 CA080621 (to Bradford EM); an Institutional Development Award from the National Institute of General Medical Sciences of the National Institutes of Health, No. 8 P20GM103527-05; and American Physiological Society STEP-UP Fellowship (to Thompson CA).

Repository Citation

Bradford, Emily M.; Thompson, Corey A.; Goretsky, Tatiana; Yang, Guang-Yu; Rodriguez, Luz M.; Li, Linheng; and Barrett, Terrence A., "Myo-Inositol Reduces β-Catenin Activation in Colitis" (2017). Internal Medicine Faculty Publications. 115.
https://uknowledge.uky.edu/internalmedicine_facpub/115